DDInter119 DDInter1094
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Lorlatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Lorlatinib may lead to a major life threatening interaction when taken with Venetoclax
Lorlatinib may lead to a major life threatening interaction when taken with Lurbinectedin